Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hBMMSC in Autism Spectrum Disorder
NCT07177677Phase 1Not yet recruiting
- Sponsor
- Jiuzhitang Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label trial of human bone marrow mesenchymal stem cells (Jiuzhitang Maker) in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Jiuzhitang Co., Ltd. Primary endpoint: Safety Evaluation of hBMMSC Injection in ASD Patients at 48 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
human bone marrow mesenchymal stem cells (Jiuzhitang Maker)
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07177677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177677.